ScholarIQanswers from OpenAlex
Celldex Therapeutics (United States)
InstitutionResearch output, impact & collaborations
Celldex Therapeutics (United States) is a institution indexed in ScholarIQ from OpenAlex.
What is known about Celldex Therapeutics (United States)?
ScholarIQrecord summary
Celldex Therapeutics (United States) is a research organisation in Hampton, US. OpenAlex records 449 works and 60,922 citations for it. 286 researchers list it as their most recent affiliation.
How many works does Celldex Therapeutics (United States) have?
ScholarIQindexed works
Celldex Therapeutics (United States) has 449 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Celldex Therapeutics (United States) have?
ScholarIQcitation count
Celldex Therapeutics (United States) has 60,922 citations in the OpenAlex counts ScholarIQ stores.
How many researchers are at Celldex Therapeutics (United States)?
ScholarIQresearcher count
Celldex Therapeutics (United States) has 286 researchers in the ScholarIQ index.
What is the average h-index at Celldex Therapeutics (United States)?
ScholarIQavg h-index
Celldex Therapeutics (United States) has an average h-index of 65.3 in OpenAlex.
What is the ROR of Celldex Therapeutics (United States)?
ScholarIQror
The ROR for Celldex Therapeutics (United States) is on the source record.
What is the OpenAlex record for Celldex Therapeutics (United States)?
ScholarIQopenalex
The OpenAlex for Celldex Therapeutics (United States) is on the source record.
Who are the most-cited researchers behind Celldex Therapeutics (United States)?
ScholarIQtop researchers by citations
What are the most-cited papers on Celldex Therapeutics (United States)?
ScholarIQmost cited works
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Edward B. Garon, Naiyer A. Rizvi, Rina Hui, Natasha B. Leighl, Ani Sarkis Balmanoukian, Joseph P. Eder, Amita Patnaik, Charu Aggarwal, Matthew A. Gubens, Leora Horn, Enric Carcereny, Myung‐Ju Ahn, Enriqueta Felip, Jong-Seok Lee, Matthew D. Hellmann, Omid Hamid, Jonathan W. Goldman, Jean‐Charles Soria, Marisa Dolled‐Filhart, Ruth Z. Rutledge, Jin Zhang, Jared Lunceford, Reshma Rangwala, Gregory M. Lubiniecki, Charlotte Roach, Kenneth Emancipator, Leena Gandhi
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
Eunice L. Kwak, Yung‐Jue Bang, D. Ross Camidge, Alice T. Shaw, Benjamin Solomon, Robert G. Maki, Sai‐Hong Ignatius Ou, Bruce J. Dezube, Pasi A. Jänne, Daniel B. Costa, Marileila Varella‐Garcia, Woo Ho Kim, Thomas J. Lynch, Panos Fidias, Hannah Stubbs, Jeffrey A. Engelman, Lecia V. Sequist, Weiwei Tan, Leena Gandhi, Mari Mino–Kenudson, Greg C. G. Wei, S. Martin Shreeve, Mark J. Ratain, Jeffrey Settleman, James G. Christensen, Daniel A. Haber, Keith D. Wilner, Ravi Salgia, Geoffrey I. Shapiro, Jeffrey W. Clark, A. John Iafrate
Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints
Shohei Koyama, Esra A. Akbay, Yvonne Y. Li, Grit S. Herter-Sprie, Kevin A. Buczkowski, William G. Richards, Leena Gandhi, Amanda J. Redig, Scott J. Rodig, Hajime Asahina, Robert E. Jones, Meghana Kulkarni, Mari Kuraguchi, Sangeetha Palakurthi, Peter E. Fecci, Bruce E. Johnson, Pasi A. Jänne, Jeffrey A. Engelman, Sidharta P. Gangadharan, Daniel B. Costa, Gordon J. Freeman, Raphael Bueno, F. Stephen Hodi, Glenn Dranoff, Kwok‐Kin Wong, Peter S. Hammerman
Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study
D. Ross Camidge, Yung‐Jue Bang, Eunice L. Kwak, A. John Iafrate, Marileila Varella‐Garcia, Stephen B. Fox, Gregory J. Riely, Benjamin Solomon, Sai‐Hong Ignatius Ou, Dong‐Wan Kim, Ravi Salgia, P. Fidias, Jeffrey A. Engelman, Leena Gandhi, Pasi A. Jänne, Daniel B. Costa, Geoffrey I. Shapiro, Patricia LoRusso, Katherine Ruffner, Patricia Stephenson, Yiyun Tang, Keith D. Wilner, Jeffrey W. Clark, Alice T. Shaw
Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer
Scott Gettinger, Leora Horn, Leena Gandhi, David R. Spigel, Scott Antonia, Naiyer A. Rizvi, John D. Powderly, Rebecca S. Heist, Richard D. Carvajal, David M. Jackman, Lecia V. Sequist, David C. Smith, Philip D. Leming, David P. Carbone, Mary Pinder-Schenck, Suzanne L. Topalian, F. Stephen Hodi, Jeffrey A. Sosman, Mario Sznol, David F. McDermott, Drew M. Pardoll, Vindira Sankar, Christoph M. Ahlers, Mark Salvati, Jon M. Wigginton, Matthew D. Hellmann, Georgia Kollia, Ashok Gupta, Julie R. Brahmer
How much of the research on Celldex Therapeutics (United States) is open access?
ScholarIQopen access share
67%OPEN ACCESS